The doors of precision: Reenergizing psychiatric drug development with psychedelics and open access computational tools (Barron and Friedman)

Published: Mar 16, 2022
Science Advances

~

Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences (Ballentine et al.)

Published: Mar 16, 2022
Science Advances

~

Reply to: 5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous (James et al.)

Published: Mar 17, 2022
Human Psychopharmacology

~

5-MeO-DMT has not been found in traditional ayahuasca preparations and the combination of 5-MeO-DMT with MAOIs is dangerous (Lancelotta)

Published: Mar 17, 2022
Human Psychopharmacology

~

Phenomenological assessment of psychedelics induced experiences: Translation and validation of the German Challenging Experience Questionnaire (CEQ) and Ego-Dissolution Inventory (EDI) (Dworatzyk et al.)

Published: Mar 16, 2022
PLoS ONE

~

A mind-changing approach to the therapeutic use of psychedelics (Osman)

Published: Mar 17, 2022
Nature Structural & Molecular Biology

~

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline (De Gregorio et al.)

Published: Mar 17, 2022
Neuropsychopharmacology

~

The promises and perils of psychedelic pharmacology for psychiatry (McClure-Begley and Roth)

Published: Mar 17, 2022
Nature Reviews Drug Discovery

~

Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability (Rossi et al.)

Published: Mar 18, 2022
Expert Opinion on Drug Safety

~

Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials (Roscoe and Lozy)

Published: Mar 16, 2022
Drug Science, Policy and Law

~

Reduced Precision Underwrites Ego Dissolution and Therapeutic Outcomes Under Psychedelics (Stoliker et al.)

Published: Mar 17, 2022
Frontiers in Neuroscience

~

Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada (Argento et al.)

Published: Mar 16, 2022
Drug and Alcohol Dependence Reports

~

Cannabinoids and Psychedelics for Neuropsychiatric Symptoms of Alzheimer’s: Addressing Disparities Through Clinical Trials (Forester et al.)

Published: Mar 16, 2022
The American Journal of Geriatric Psychiatry

~

3,4-Methylenedioxymethamphetamine Quantification via Benchtop 1H qNMR Spectroscopy: Method Validation and its Application to Ecstasy Tablets Collected at Music Festivals (Frinculescu et al.)

Published: Mar 16, 2022
J Pharm Biomed Anal